A review of bioactive plant polysaccharides: Biological activities, functionalization, and biomedical applications
Natural polysaccharides from different sources have long been studied and widely used in
different areas, such as food and feed, medicine and pharmaceutics, and in papermaking. In …
different areas, such as food and feed, medicine and pharmaceutics, and in papermaking. In …
Pathogenesis of mucopolysaccharidoses, an update
S Fecarotta, A Tarallo, C Damiano, N Minopoli… - International Journal of …, 2020 - mdpi.com
The recent advancements in the knowledge of lysosomal biology and function have
translated into an improved understanding of the pathophysiology of …
translated into an improved understanding of the pathophysiology of …
[PDF][PDF] Mucopolysaccharidosis VI: pathophysiology, diagnosis and treatment
P Harmatz, R Shediac - Front Biosci (Landmark Ed), 2017 - article.imrpress.com
1. ABSTRACT Mucopolysaccharidosis VI (MPS VI), or Maroteaux-Lamy syndrome, is an
autosomal recessive lysosomal storage disorder caused by deficient activity of the enzyme …
autosomal recessive lysosomal storage disorder caused by deficient activity of the enzyme …
Recommendations for the management of MPS IVA: systematic evidence-and consensus-based guidance
MU Akyol, TD Alden, H Amartino, J Ashworth… - Orphanet journal of rare …, 2019 - Springer
Abstract Introduction Mucopolysaccharidosis (MPS) IVA or Morquio A syndrome is an
autosomal recessive lysosomal storage disorder (LSD) caused by deficiency of the N …
autosomal recessive lysosomal storage disorder (LSD) caused by deficiency of the N …
Lysosomal storage diseases: current therapies and future alternatives
Lysosomal storage disorders (LSDs) are a group of monogenic diseases characterized by
progressive accumulation of undegraded substrates into the lysosome, due to mutations in …
progressive accumulation of undegraded substrates into the lysosome, due to mutations in …
Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future
DAH Whiteman, A Kimura - Drug design, development and therapy, 2017 - Taylor & Francis
Mucopolysaccharidosis type II (MPS II; Hunter syndrome; OMIM 309900) is a rare,
multisystemic, progressive lysosomal storage disease caused by deficient activity of the …
multisystemic, progressive lysosomal storage disease caused by deficient activity of the …
Novel therapies for mucopolysaccharidosis type III
B Seker Yilmaz, J Davison, SA Jones… - Journal of inherited …, 2021 - Wiley Online Library
Abstract Mucopolysaccharidosis type III (MPS III) or Sanfilippo disease is an orphan
inherited lysosomal storage disease and one of the most common MPS subtypes. The …
inherited lysosomal storage disease and one of the most common MPS subtypes. The …
Innate immunity in mucopolysaccharide diseases
O Mandolfo, H Parker, B Bigger - International Journal of Molecular …, 2022 - mdpi.com
Mucopolysaccharidoses are rare paediatric lysosomal storage disorders, characterised by
accumulation of glycosaminoglycans within lysosomes. This is caused by deficiencies in …
accumulation of glycosaminoglycans within lysosomes. This is caused by deficiencies in …
Therapies for the bone in mucopolysaccharidoses
Patients with mucopolysaccharidoses (MPS) have accumulation of glycosaminoglycans in
multiple tissues which may cause coarse facial features, mental retardation, recurrent ear …
multiple tissues which may cause coarse facial features, mental retardation, recurrent ear …
Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux–Lamy syndrome)—10‐year follow‐up of patients who previously …
R Giugliani, C Lampe, N Guffon… - American journal of …, 2014 - Wiley Online Library
Mucopolysaccharidosis VI (MPS VI) is a clinically heterogeneous and progressive disorder
with multiorgan manifestations caused by deficient N‐acetylgalactosamine‐4‐sulfatase …
with multiorgan manifestations caused by deficient N‐acetylgalactosamine‐4‐sulfatase …